长春地辛联合化疗78例晚期非小细胞肺癌

Study on vindesine (VDS) in treatment of 78 cases of advanced non-small cell lung cancer (NSCLC) by combined chemotherapy

目的观察长春地辛(VDS)对NSCLC的疗效和毒副作用VDS。评价VDS与CAP方案联合应用的协同作用。方法142例NSCLC病人被随机分成两组:78例病人给CAP+VDS方案治疗,64例病人给CAP方案治疗。两组病人各方面具有可比性。结果CAP+VDS组有效率为41.9%明显高于CAP组的16.7%(P<0.05)。VDS的主要毒副作用为骨髓抑制、周围神经毒性和静脉炎。结论国产VDS对NSCLC疗效肯定,VDS与CAP方案联合治疗NSCLC具有协同作用,疗效良好,毒副作用可以耐受。

Objective To evaluate the efficacy of VDS in NSCLC patients and to observe the side effects of VDS. Methods One-hundred-forty-two patients with advanced NSCLS (stage Ⅲ b or Ⅳ) were divided into 2 groups randomly> given CAP + VDS (n = 78) or CAP (n = 64) regiments. The characteristics of the patients were well -ballanced between the 2 groups with regards to sex, age, performance status, stage, histology and previous treatment with chemotherapy. Results The response rate (41. 9%) in the CAP+VDS group was higher than that (16. 7%) in the CAP group. The main side effects of VDS group were myelosuppression, peripheral neuropathy and mild phlebitis. The dose limiting toxicity of CAP+VDS regimen was myelosuppression. Conclusion The efficacy of VDS to NSCLS has been confirmed. There are some supplementative effects when VDS was used combined with CAP regimen with tolerable side effects.